Adolescent Female Acne: Etiology and Management

White, 1998, Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris, J Am Acad Dermatol, 39, S34, 10.1016/S0190-9622(98)70442-6 Sathakis, 1997, Descriptive epidemiology of acne vulgaris in the community, Australas J Dermatol, 38, 115, 10.1111/j.1440-0960.1997.tb01126.x Lehmann, 2002, Acne therapy: a methodologic review, J Am Acad Dermatol, 47, 231, 10.1067/mjd.2002.120912 James, 2000, Andrews' Diseases of the Skin Bataille, 2002, The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women, J Invest Dermatol, 119, 1317, 10.1046/j.1523-1747.2002.19621.x Yosipovitch, 2007, Study of psychological stress, sebum production and acne vulgaris in adolescents, Acta Derm Venereol, 87, 135, 10.2340/00015555-0231 Thiboutot, 2000, New treatments and therapeutic strategies for acne, Arch Fam Med, 9, 179, 10.1001/archfami.9.2.179 Adebamowo, 2005, High school dietary dairy intake and teenage acne, J Am Acad Dermatol, 52, 207, 10.1016/j.jaad.2004.08.007 Thiboutot, 1999, Androgen metabolism in sebaceous glands from subjects with and without acne, Arch Dermatol, 135, 1041, 10.1001/archderm.135.9.1041 Cibula, 2000, The role of androgens in determining acne severity in adult women, Br J Dermatol, 143, 399, 10.1046/j.1365-2133.2000.03669.x Khoiny, 1996, Use of depo-provera in teens, J Pediatr Health Care, 10, 195, 10.1016/S0891-5245(96)90001-2 Hartgens, 2004, Effects of androgenic-anabolic steroids in athletes, Sports Med, 34, 513, 10.2165/00007256-200434080-00003 Chi, 1991, An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs, Contraception, 44, 573, 10.1016/0010-7824(91)90078-T Strauss, 2007, Guidelines of care for acne vulgaris management, J Am Acad Dermatol, 56, 651, 10.1016/j.jaad.2006.08.048 Escobar-Morreale, 2004, Macroprolactinemia in women presenting with hyperandrogenic symptoms: implications for the management of polycystic ovary syndrome, Fertil Steril, 82, 1697, 10.1016/j.fertnstert.2004.06.045 Haider, 2004, Treatment of acne vulgaris, JAMA, 292, 726, 10.1001/jama.292.6.726 Leyden, 2006, Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris, J Am Acad Dermatol, 54, 73, 10.1016/j.jaad.2005.04.046 Glass, 1999, A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris, Dermatol, 199, 242, 10.1159/000018255 Zouboulis, 2000, A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris, Br J Dermatol, 143, 498, 10.1111/j.1365-2133.2000.03701.x Lookingbill, 1997, Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations, J Am Acad Dermatol, 37, 590, 10.1016/S0190-9622(97)70177-4 Goodfellow, 1984, Oral spironolactone improves acne vulgaris and reduces sebum excretion, Br J Dermatol, 11, 209, 10.1111/j.1365-2133.1984.tb04045.x Muhlemann, 1986, Oral spironolactone: an effective treatment for acne vulgaris in women, Br J Dermatol, 115, 227, 10.1111/j.1365-2133.1986.tb05722.x Carmina, 2002, A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women, Clin Endocrinol, 57, 231, 10.1046/j.1365-2265.2002.01594.x Thorneycroft, 1999, Effect of low-dose oral contraceptives on androgenic markers and acne, Contraception, 60, 255, 10.1016/S0010-7824(99)00093-1 Arowojolu, 2007, Combined oral contraceptive pills for treatment of acne: Review, Cochrane Database Syst Rev, 24, 10.1002/14651858.CD004425.pub3 Rabe, 2000, Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro, Gynecol Endocrinol, 14, 223, 10.3109/09513590009167685 Redmond, 1997, Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial, Obstet Gynecol, 89, 615, 10.1016/S0029-7844(97)00059-8 Lucky, 1997, Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris, J Am Acad Dermatol, 37, 746, 10.1016/S0190-9622(97)70112-9 Maloney, 2001, Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris, Clin J Womens Health, 2, 123, 10.1053/cjwh.2001.25638 Huber, 2006, Treating acne with oral contraceptives: use of lower doses, Contraception, 73, 23, 10.1016/j.contraception.2005.07.010 Thioboutot, 2001, A randomized, controlled trial of a low-dose contraceptive containing 20 ug of ethinyl estradiol and 100ug of levonorgestrel for acne treatment, Fertil Steril, 76, 461, 10.1016/S0015-0282(01)01938-0 Leyden, 2002, Efficacy of a low-dose oral contraceptive containing 20μg of ethinyl estradiol and 100 μg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial, J Am Acad Dermatol, 47, 399, 10.1067/mjd.2002.122192 Rapkin, 2007, Drospirenone: a novel progestin, Expert Opin Pharmacother, 8, 989, 10.1517/14656566.8.7.989 Thorneycroft, 2004, Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment, Cutis, 74, 123 Shaw, 2000, Low-dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients, J Am Acad Dermatol, 43, 498, 10.1067/mjd.2000.105557 Thiboutot, 2001, Hormones and acne: pathophysiology, clinical evaluation and therapies, Sem Cutan Med Surg, 20, 144, 10.1053/sder.2001.28208 Rosenberg, 2000, Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 μg and 35 μg estrogen preparations, Contraception, 60, 32 Sherif, 1999, Benefits and risks of oral contraceptives, Am J Obstet Gyn, 180, 343, 10.1016/S0002-9378(99)70694-0 Lidegaard, 1999, Smoking and use of oral contraceptives: Impact on thrombotic diseases, Am J Obstet Gyn, 180, 357, 10.1016/S0002-9378(99)70696-4